Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.

Mohd Masnoon Saiyed Joshua M Byrnes Tushar Srivastava Paul A Scuffham Martin J Downes

Published in: Clinical drug investigation (2020)

Our study found that, at current prices, lenvatinib is a cost-effective treatment option compared with sorafenib for the first-line treatment of patients with advanced HCC.

Keyphrases

replacement therapy